Skip to main content

A Year Ago: Aug 1, 2002

Premium

A year ago, GT’s cover story profiled New York-based ProteoMetrics, a software vendor using protein identification algorithms developed in chairman Brian Chait’s Rockefeller University lab. Times have definitely changed for the young company, which was shelled out by its collaborator, Genomic Solutions of Ann Arbor, Mich. The software became the foundation for Genomic Solutions’ new subsidiary, Proteomic Solutions, which was formerly the 11-person Winnipeg office of ProteoMetrics, headed up by once-CEO Ron Beavis. David Fenyo, the CSO and president of ProteoMetrics, joined Genomic Solutions as director of proteomics. Chait, meanwhile, returned to his Rockefeller lab, while the 40 New York-based employees of ProteoMetrics were sent packing.

The August 2001 issue also took readers on a tour of genomics hotbed North Carolina, which continues to lure companies and research with its heavy investments in the field. One feature looked at SAS spinout iBiomatics, located near Research Triangle Park in Cary. Since then, iBiomatics has spun back into SAS, and its bioinformatics products are sold now under the SAS brand. GT has looked at other RTP companies since then, including Saffron Technology, a data-mining company looking to get into the life sciences market.

— Amanda Urban

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.